Hospitals
Physicians
Clinical trials
Contact us
Links
National Cancer Institute - Community Clinical Oncology Program

 

CURRENTLY OPEN CLINICAL TRIALS

Dayton Clinical Oncology Program accesses clinical trials through its membership in cooperative research groups funded by the National Cancer Institute (NCI), and through the pharmaceutical industry.

For a listing of research groups and links to their web sites, go to the "Links to Other Sites" tab at the left.

Clinical Trial By Disease Site
(Click the links to advance to a specific section)

   

 

Descriptions of these clinical trials are available on http://www.ClinicalTrials.gov



General Cancer Control Trials for Symptom Management

URCC-10055

Assessment Of Cognitive Function In Breast Cancer And Lymphoma Patients Receiving Chemotherapy At Pre-Treatment, Post-Treatment And At Six Month Follow-Up

URCC-14040

A Randomized Clinical Trial Comparing the Effectiveness of Yoga, Survivorship Health Education, and Cognitive Behavioral Therapy for Treating Insomnia in Cancer Survivors

URCC-13059

Gap 70 + ;  A Geriatric Assessment Intervention For Patients Aged 70 And Over Receiving Chemotherapy For Advanced Cancer: Reducing Chemotherapy Toxicity In Older Adults 

Back to top

BRAIN

Glioblastoma:

A071102

Veliparib Or Placebo In Combination With Adjuvant Temozolomide In Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Meningioma:

A071401

Trial Of SMO/AKT/Nf2 Inhibitors In Progressive Meningiomas With SMO/AKT/Nf2 Mutations

Metastases:

A221208

Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases

NRG-CC001

Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases

Back to list

Descriptions of these clinical trials are available on http://www.ClinicalTrials.gov

BREAST

BREAST CANCER CONTROL:

A221102

Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgias

A221405

A Study Evaluating The Pregnancy Outcomes And Safety Of Interrupting Endocrine
Therapy For Young Women With Endocrine Responsive Breast Cancer Who Desire
Pregnancy (Positive)

E1Z11

Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

SCUSF-1102

A Cluster Randomized Controlled Trial Comparing Interventions to Enhance Utilization of Genetics Services Among Breast Cancer Patients

Back to list

HER2-

S1207

Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy.

HER2-/BRACA+

NSABP B-55

Study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy

HER2-/ER+

A011106

ALTernate approaches for Clinical Stage II or III Estrogen Receptor positive breast cancer Neo Adjuvant TrEatment (ALTERNATE) in postmenopausel women:

METASTATIC:

NRG-BR002

Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer

Nodal:

NRG-BR003

Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node- Positive or High-Risk Node-Negative Triple Negative Invasive Breast Cancer

Triple Negative

EA1131

Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following
Neoadjuvant Chemotherapy

S1416

Trial of Cisplatin with or without Veliparib in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.

Back to list

 

Descriptions of these clinical trials are available on http://www.ClinicalTrials.gov

 

GASTROINTESTINAL:

COLORECTAL CANCER PREVENTION:

S0820

Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)

COLORECTAL TREATMENT:

LIVER:

NRG-GI001

Focal Radiation Therapy For Unresectable, Localized Intrahepatic Cholangiocarcinoma

 

PANCREATIC:

EA2142

Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas

S1505

Study of Perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma.

 

RECTAL:

NRG-GI002

Evaluation of Copanlisib (BAY 80-6946), (IND #130822), A Selective Inhibitor of PI3KCA, in Patients with Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations

N1048

Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision

Back to list

 

Descriptions of these clinical trials are available on http://www.ClinicalTrials.gov

 

GENITOURINARY:

PROSTATE:

S1216

Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer

RENAL:

E2810

Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy

Urothelial:

EA8141

Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma

Back to list

GYN:

Endometrial:

GOG-0286B Temporarily closed to accrual

Study Of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo As Initial Therapy For Measurable Stage III Or IVA, Stage IVB, or Recurrent Endometrial Cancer

Ovarian:

GOG-0213

Trial Of Carboplatin And Paclitaxel (Or Gemcitabine) Alone Or In Combination With Bevacizumab (Nsc #704865, Ind #113912) Followed By Bevacizumab And Secondary Cytoreductive Surgery In Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary And Fallopian Tube Cancer. Nci-Supplied Agents: Bevacizumab

Other:

NRG-GY004

study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer

NRG-GY005

Study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)

NRG-GY006

A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer.

 

Descriptions of these clinical trials are available on http://www.ClinicalTrials.gov

HEAD and NECK

A091404

Study Of Enzalutamide For Patients With Androgen Receptor Positive Salivary Cancers

EA3132

Adjuvant Radiotherapy with or without Cisplatin for P53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)

LEUKEMIA:

ALL:

E1910

Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults

S1318

Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517) , Prednisone and Blinatumomab for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL


LUNG:

NSCLC:

A151216 (ALCHEMIST)

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

A081105 (ALCHEMIST)

Study Of Erlotinib Or Placebo In Patients With Completely Resected Epidermal Growth Factor Receptor (EGRF) Mutant Non-Small Cell Lung Cancer (NSCLC)

E4512 (ALCHEMIST)

Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

EA5123

Role of Early 18F-FDG-PET/CT Scan in Predicting Mediastinal Downstaging with Neoadjuvant Chemotherapy in Resectable Stage III A NSCLC

EA5142 (ALCHEMIST)
A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
S1403

Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC)

S1507

Trial of Trametinib with Docetaxel in Patients with Kras Mutation Positive Non-Small Cell Lung Cancer and Progressive Disease Following One or Two Prior Systemic Therapies.

WF-01414

Improving Resection Rates among African Americans with NSCLC (“Southern Lung Cancer Study”)

SCLC

NRG-CC003

Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer

SQUAMOUS CELL

S1400

Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer

Descriptions of these clinical trials are available on http://www.ClinicalTrials.gov

LYMPHOMA:

 

Back to list

MELANOMA:

BRAFV600 Mutant

EA6134

Trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

S1320

Trial Of Intermittent Versus Continuous Dosing Of Dabrafenib (NSC-763760) And Trametinib (NSC-763093) In BRAF V600E/K Mutant Melanoma

Resected

S1404

Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma.

Unresectable

E3612

Trial of Ipilimumab with or without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma

EA6141

Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

MYELOMA:

A061402

Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment with Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy.

E1A11

Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeoma

E3A06

Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma

S1211 Temporarily closed to accrual

Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)

Back to list

Descriptions of these clinical trials are available on http://www.ClinicalTrials.gov

OTHER:

EAY131

Molecular Analysis for Therapy Choice (MATCH)

Germ Cell

A031102

Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors

Molecular Profiling

9671

Exceptional Responders Pilot study: Molecular profiling of tumors from cancer patients who are Exceptional responders

 

Descriptions of these clinical trials are available on http://www.ClinicalTrials.gov

 

QUESTIONS?

CONTACT DAYTON CLINICAL ONCOLOGY PROGRAM
OR ASK YOUR PHYSICIAN
"Is There a Clinical Trial For Me?"

Contact Us

By Phone:
(937) 775-1350
Fax:
(937) 775-1358
By Mail:
Dayton Clinical Oncology Program
3123 Research Blvd., Suite 150
Dayton, Ohio 45420